Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice

被引:0
|
作者
Xu, Xiao [1 ,2 ]
Kwiatek, Justin [2 ]
Siddall, James [3 ]
Genofre, Eduardo [4 ]
Stirnadel-Farrant, Heide [5 ]
Katial, Rohit [2 ]
机构
[1] AstraZeneca, BioPharmaceut Market Access & Pricing, 200 Orchard Ridge Dr, Gaithersburg, MD 20878 USA
[2] AstraZeneca, BioPharmaceut Med, 200 Orchard Ridge Dr, Gaithersburg, MD 20878 USA
[3] Adelphi Real World, Bollington, Cheshire, England
[4] AstraZeneca, BioPharmaceut Med, Wilmington, DE USA
[5] AstraZeneca, BioPharmaceut Med, Cambridge, England
关键词
Eosinophilic esophagitis; Inflammatory disease; Real-world evidence; Health-related quality of life; Disease burden; QUALITY-OF-LIFE; RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; CHILDREN; ANXIETY; ADULTS; COSTS;
D O I
10.1186/s12876-024-03334-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundEosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.MethodsData analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged >= 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of >= 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.ResultsOverall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.ConclusionsEosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN THE UNITED STATES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
    Xu, X.
    Kwiatek, J.
    Siddall, J.
    Genofre, E.
    Stirnadel-Farrant, H.
    Katial, R.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S78 - S78
  • [2] CHARACTERIZATION OF PATIENTS WITH EOSINOPHILIC ESOPHAGITIS MANAGED BY GASTROENTEROLOGISTS AND ALLERGISTS: REAL-WORLD CLINICAL PRACTICE EVIDENCE
    Xu, X.
    Kwiatek, J.
    Siddall, J.
    Genofre, E.
    Stirnadel-Farrant, H.
    Katial, R.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S78 - S78
  • [3] Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice
    Laserna-Mendieta, Emilio J.
    Casabona, Sergio
    Savarino, Edoardo
    Perello, Antonia
    Perez-Martinez, Isabel
    Guagnozzi, Danila
    Barrio, Jesus
    Guardiola, Antonio
    Asensio, Teresa
    de la Riva, Susana
    Ruiz-Ponce, Miriam
    Rodriguez-Oballe, Juan Armando
    Santander, Cecilio
    Arias, Angel
    Lucendo, Alfredo J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (13) : 2903 - +
  • [4] Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia
    Alain Schoepfer
    Alex Straumann
    Ekaterina Safroneeva
    [J]. Current Treatment Options in Gastroenterology, 2016, 14 (1) : 51 - 60
  • [5] Physician-Documented Symptoms and Treatment Among Patients With Eosinophilic Esophagitis in the United States: Evidence From Real World Clinical Practice
    Xu, Xiao
    Kwiatek, Justin
    Siddall, James
    Genofre, Eduardo
    Stirnadel-Farrant, Heide
    Katial, Rohit
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S324 - S324
  • [6] Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes
    Melanie J. Calvert
    Daniel J. O’Connor
    Ethan M. Basch
    [J]. Nature Reviews Drug Discovery, 2019, 18 : 731 - 732
  • [7] Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes
    Calvert, Melanie J.
    O'Connor, Daniel J.
    Basch, Ethan M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (10) : 731 - 732
  • [8] The patient-reported burden of alopecia areata by current severity: A real-world study in the US
    Burge, Russel Thomas
    Anderson, Peter
    Austin, Jennifer
    Piercy, James
    Manuel, Laure
    Edson-Heredia, Emily
    McCollam, Jill Shwed
    Senna, Maryanne
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB86 - AB86
  • [9] Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
    Norlin, Jenny M.
    Carlsson, Katarina Steen
    Persson, Ulf
    Schmitt-Egenolf, Marcus
    [J]. DERMATOLOGY, 2012, 225 (04) : 326 - 332
  • [10] Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
    Gomez, Alvaro
    Enman, Yvonne
    Parodis, Ioannis
    [J]. PATIENT-RELATED OUTCOME MEASURES, 2023, 14 : 1 - 13